Ireland
--:--IST
Enrolling by invitation Observational

Global Utilization And Registry Database for Improved heArt preservatioN

NCT04141605 · tracked via the Priya Life Science Spain tracker
Phase
Observational
Started
2020-02-14
Last updated
2026-10-16

Condition(s) studied

Heart DiseasesHeart FailureHeart Defects, Congenital

Investigational drug(s) / intervention(s)

SherpaPak Cardiac Transport System

SherpaPak Cardiac Transport System: The Paragonix SherpaPak Cardiac Transport System ("SherpaPak CTS") is an ultraportable hypothermic preservation and transport system intended for use with donor hearts. The device is a legally marketed, FDA cleared medical device in the United States and CE Marked medical device in the European Union. The SherpaPak CTS consists of multiple components: 1) outer transport shipper which contains within various non-ice based temperature controlled packaging elements, 2) an inner and outer hard shell assembly which provides a rigid barrier enclosure in which the heart is immersed and suspended in a cold storage solution cleared for use in storing and transporting donor hearts, 3) a data logger that monitors and displays the temperature of the cold storage solution in which the heart is stored during transport, and 4) four size heart connectors designed to accommodate various size aortic stem diameters by which donor hearts are attached.

Study summary

The primary objective of this study is to collect real-world clinical performance data to assess the clinical outcomes of patients receiving heart transplants using donor hearts transported via the SherpaPak CTS System. These results will be compared to outcomes of retrospective patients whose hearts were transported with the previous standard method.

CONCERT DCD is a substudy designed to assess the safety and feasibility of a direct procurement method for donation after circulatory death (DCD) heart procurement (CONCERT DCD) that utilizes preservation in a SherpaPak Cardiac Transport System. This DCD Substudy will be limited to approved GUARDIAN-Heart Registry sites who have been qualified to participate. The DCD Substudy will include prospective recipient identification and documentation of informed consent.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Donor and donor hearts matched to the prospective recipient based upon institutional medical practice * Registered male or female primary heart transplant candidates including pediatric candidates Exclusion Criteria: * Donor and donor hearts that do not meet institutional clinical requirements for transplantation * When safe connection with the aorta cannot be made, e.g., due to lack of enough length of the aortic root * Patients who are incarcerated persons (prisoners) * Patients who have had a previous organ transplant

Primary outcome measure(s)

  • Number of Patients with Primary Graft Dysfunction — one year
    Less than 40% LVEF by echocardiography or hemodynamics with RAP greater than 15 mm Hg, PCWP greater than 20 mm Hg, CI less thann 2 L/min/m\^2, hypotension with MAP less than 70 mm Hg (lasting more than 1 hour)
  • Number of Patients with Right Ventricular Dysfunction — one year
    hemodynamics with RAP grater than 15mm Hg, PCWP less than 15 mm Hg, CI less than 2 L/min/m\^2, TPG less than 15mm Hg/pulmonary artery systolic pressure less than 50 mmHg OR need for RVAD
  • Length of ICU Stay — one year
    Length of time patient admitted to the intensive care unit post transplant
  • Length of Hospital Stay — one year
    Length of time before patient is discharged from the hospital post transplant
  • Survival — 5 years
    The length of patient survival up to 5 years will be compared

Trial sites (22)

FacilityCityRegionStatus
Stanford University Stanford California
Medstar Washington Hospital Washington D.C. District of Columbia
University of Florida Health Shands Hospital Gainesville Florida
Mayo Clinic Jacksonville Florida
AdventHealth Orlando Orlando Florida
Lutheran Hospital Fort Wayne Indiana
Kansas University Medical Center Lawrence Kansas
Tufts University Medical Center Boston Massachusetts
Massachusetts General Hospital Boston Massachusetts
Spectrum Health Grand Rapids Michigan
NewYork-Presbyterian Columbia University Irving Medical Center New York New York
Duke University Durham North Carolina
Cincinnati Children's Hospital Cincinnati Ohio
Pennslyvania State University State College Pennsylvania
Le Bonheur Children's Hospital Memphis Tennessee
Baylor University Medical Center Dallas Texas
Sentara Healthcare Norfolk Virginia
University of Graz Graz Austria
Allgemeines Krankenhaus Wien Vienna Austria
Hospital Universitario 12 de Octubre Madrid Spain
Hospital Clínico Universitario de Valladolid Valladolid Spain
Manchester University Manchester United Kingdom
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04141605 on ClinicalTrials.gov ↗ ← All trials in Spain